• AIM ImmunoTech highlighted its ongoing Phase 2 DURIPANC trial testing Ampligen with AstraZeneca’s durvalumab as maintenance therapy in pancreatic cancer.
• No new trial results were reported; primary endpoint analyses, biomarker readouts, and overall survival follow-up are expected in the future.
• The study aims to show Ampligen can shift immunosuppressive tumors toward greater responsiveness to checkpoint inhibitors, supporting a potential pivotal program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090903PRIMZONEFULLFEED9823044) on September 09, 2026, and is solely responsible for the information contained therein.